This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Phenformin.
|
I searched "Retardo" and was redirected to this page.. ????? 72.84.76.17 ( talk) 22:51, 30 July 2014 (UTC)
The identifying numbers on the article (CAS, etc) are for phenformin. The "Chemistry and Pharmacokinetics" section discusses phenformin hydrochloride, which has different identifying numbers. — Preceding
unsigned comment added by
69.193.84.250 (
talk) 17:37, 23 March 2015 (UTC)
Formerly the anticancer was a work of WP:OR, picking and choosing this and that primary source to tell a story. This is not how we edit WP. Here is the section as it was:
Phenformin, along with
buformin and
metformin, inhibits the growth and development of cancer. Respective studies were initiated by Vladimir Dilman (see f.e.
[1]
[2]
[3]
[4]
[5]
[6] The anticancer property of these drugs may be due to their ability to disrupt the
Warburg effect and revert the cytosolic glycolysis characteristic of cancer cells to normal oxidation of pyruvate by the mitochondria.
[7] Metformin reduces liver glucose production in diabetics and disrupts the Warburg effect in cancer by
AMPK activation and inhibition of the
mTor pathway.
[8]
Recent studies have shown that phenformin and metformin are inhibitors of mitochondrial complex I, the former drug being more potent. Phenformin is less polar and more lipid soluble and exhibits a higher affinity for mitochondrial membranes than metformin. [9] It has been demonstrated that phenformin also inhibits mitochondrial complex I to exert its antitumor effects in experimental models of cancer. [10]
References
I replaced that with this, sourced to recent secondary sources, as every content policy calls us to do:
Vladimir Dilman first proposed in 1971 that biguanides like metformin and phenformin may have potential to treat cancer, prevent cancer, and to extend life, an idea that was subsequently supported by in vitro and animal studies, as well as an apparent reduction in the incidence of cancer in people taking metformin for diabetes. [1] Laboratory studies attribute these apparent effects to inhibition of mTOR [1] inhibition of complex I, [2] and inhibition of AMP-activated protein kinase. [3]
References
- Jytdog ( talk) 02:48, 23 March 2016 (UTC)
This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Phenformin.
|
I searched "Retardo" and was redirected to this page.. ????? 72.84.76.17 ( talk) 22:51, 30 July 2014 (UTC)
The identifying numbers on the article (CAS, etc) are for phenformin. The "Chemistry and Pharmacokinetics" section discusses phenformin hydrochloride, which has different identifying numbers. — Preceding
unsigned comment added by
69.193.84.250 (
talk) 17:37, 23 March 2015 (UTC)
Formerly the anticancer was a work of WP:OR, picking and choosing this and that primary source to tell a story. This is not how we edit WP. Here is the section as it was:
Phenformin, along with
buformin and
metformin, inhibits the growth and development of cancer. Respective studies were initiated by Vladimir Dilman (see f.e.
[1]
[2]
[3]
[4]
[5]
[6] The anticancer property of these drugs may be due to their ability to disrupt the
Warburg effect and revert the cytosolic glycolysis characteristic of cancer cells to normal oxidation of pyruvate by the mitochondria.
[7] Metformin reduces liver glucose production in diabetics and disrupts the Warburg effect in cancer by
AMPK activation and inhibition of the
mTor pathway.
[8]
Recent studies have shown that phenformin and metformin are inhibitors of mitochondrial complex I, the former drug being more potent. Phenformin is less polar and more lipid soluble and exhibits a higher affinity for mitochondrial membranes than metformin. [9] It has been demonstrated that phenformin also inhibits mitochondrial complex I to exert its antitumor effects in experimental models of cancer. [10]
References
I replaced that with this, sourced to recent secondary sources, as every content policy calls us to do:
Vladimir Dilman first proposed in 1971 that biguanides like metformin and phenformin may have potential to treat cancer, prevent cancer, and to extend life, an idea that was subsequently supported by in vitro and animal studies, as well as an apparent reduction in the incidence of cancer in people taking metformin for diabetes. [1] Laboratory studies attribute these apparent effects to inhibition of mTOR [1] inhibition of complex I, [2] and inhibition of AMP-activated protein kinase. [3]
References
- Jytdog ( talk) 02:48, 23 March 2016 (UTC)